Related Experiment Video
Updated: Jun 12, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Cell distribution after intracoronary bone marrow stem cell delivery in damaged and undamaged myocardium:
Virginie F Forest1, Ashok M Tirouvanziam, Christian Perigaud
1INSERM UMR915, l'institut du thorax, IRT-Université de Nantes, 8 quai Moncousu, BP 70721, Nantes, F-44007 Cedex 1, France. virginie.forest@univ-nantes.fr
Insights
Intracoronary injection effectively delivers autologous bone marrow mononuclear cells to the heart, unlike intravenous delivery. Cell distribution to the myocardium after intracoronary injection is independent of myocardial infarction presence.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Therapy
Background:
- Contradictory results from early stem cell therapy trials necessitate better protocol evaluation.
- Autologous bone marrow mononuclear cells (BMMNCs) are a focus for cardiac repair.
- Porcine models offer insights into cell distribution for myocardial infarction.
Purpose of the Study:
- To compare whole body and cardiac cell distribution after intracoronary versus peripheral intravenous injection of BMMNCs.
- To evaluate cell homing in a porcine acute myocardial infarction model.
- To assess the impact of myocardial infarction on cell retention.
Main Methods:
- Induction of myocardial infarction in domestic pigs.
- Labeling of 1 x 10(8) autologous BMMNCs with fluorescent markers and/or 99mTc radiotracer.
- Delivery of labeled BMMNCs via intracoronary or peripheral intravenous injection (leg vein) seven days post-infarction.
Main Results:
- Significant cardiac cell retention (6 ± 1.7%) observed 24 hours post-intracoronary injection.
- No cardiac homing detected 24 hours post-intravenous injection; cells primarily localized in the lungs.
- Myocardial retention was similar in the presence or absence of myocardial infarction.
- Histology confirmed BMMNC presence in the injected myocardium without arterial occlusion.
Conclusions:
- Peripheral intravenous BMMNC injection is ineffective for myocardial targeting.
- Intracoronary BMMNC delivery to the myocardium is independent of infarction status.
- Findings suggest potential utility for intracoronary cell therapy in chronic heart failure or ischemic myocardium without acute infarction.
Introduction:
Early randomized clinical trials of autologous bone marrow cardiac stem cell therapy have reported contradictory results highlighting the need for a better evaluation of protocol designs. This study was designed to quantify and compare whole body and heart cell distribution after intracoronary or peripheral intravenous injection of autologous bone marrow mononuclear cells in a porcine acute myocardial infarction model with late reperfusion.
Methods:
Myocardial infarction was induced using balloon inflation in the left coronary artery in domestic pigs. At seven days post-myocardial infarction, 1 x 10(8) autologous bone marrow mononuclear cells were labeled with fluorescent marker and/or 99mTc radiotracer, and delivered using intracoronary or peripheral intravenous injection (leg vein).
Results:
Scintigraphic analyses and Upsilon-emission radioactivity counting of harvested organs showed a significant cell fraction retained within the heart after intracoronary injection (6 +/- 1.7% of injected radioactivity at 24 hours), whereas following peripheral intravenous cell injection, no cardiac homing was observed at 24 hours and cells were mainly detected within the lungs. Importantly, no difference was observed in the percentage of retained cells within the myocardium in the presence or absence of myocardial infarction. Histological evaluation did not show arterial occlusion in both animal groups and confirmed the presence of bone marrow mononuclear cells within the injected myocardium area.
Conclusions:
Intravenous bone marrow mononuclear cell injection was ineffective to target myocardium. Myocardial cell distribution following intracoronary injection did not depend on myocardial infarction presence, a factor that could be useful for cardiac cell therapy in patients with chronic heart failure of non-ischemic origin or with ischemic myocardium without myocardial infarction.
More Related Videos
11:37Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...